Company: KROS
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001664710-25-000018
Chunk: 54

Company: Keros Therapeutics, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 9B
Chunk 54
---
 stock options398,525 — 12,141 — 12,141 Stock-based compensation— — 34,872 — 34,872 Net loss— — — (187,353)(187,353)BALANCE, December 31, 202440,554,705 $4 $1,140,328 $(568,779)$571,553 

See notes to consolidated financial statements.

F-6

KEROS THERAPEUTICS, INC.

Consolidated Statements of Cash Flows

(In thousands)YEAR ENDED DECEMBER 31,202420232022CASH FLOWS FROM OPERATING ACTIVITIES:Net loss$(187,353)$(152,992)$(104,679)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation expense1,229 815 674 Loss on disposal of fixed asset— 4 12 Stock-based compensation expense34,872 28,763 18,682 Non-cash lease expense1,820 1,552 941 Changes in operating assets and liabilities:Accounts receivable(2,599)(143)18,000 Prepaid expenses and other current assets(10,217)(9,284)(3,321)Other assets(4)(478)(1,574)Accounts payable(249)1,614 (408)Right-of-use assets and operating lease liabilities (1,320)384 (3,711)Accrued expenses and other current liabilities2,952 5,257 5,322 Net cash used in operating activities(160,869)(124,508)(70,062)CASH FLOWS FROM INVESTING ACTIVITIES:Purchase of property and equipment(1,931)(2,464)(1,241)Net cash used in investing activities(1,931)(2,464)(1,241)CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from issuance of common stock, net of underwriting discounts151,340 — — Payment of issuance costs(283)— — Proceeds from issuance of common stock under the ATM agreement, net of commissions228,794 175,825 119,578 Payment of issuance costs associated with issuance of common stock under the ATM agreement(171)(94)(87)Proceeds from exercise of stock options12,141 3,225 818